Department of Nutrition and Food Science, College Station, TX 77843, USA.
Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Nutr Res. 2020 Mar;75:85-94. doi: 10.1016/j.nutres.2020.01.002. Epub 2020 Jan 10.
Inflammatory bowel disease (IBD) characterized by chronic intestinal inflammation and intestinal microbial dysbiosis present a major risk factor in the development of colorectal cancer. Previously, dietary polyphenols from mango (Mangifera indica L.) such as gallotannins and gallic acid have been shown to mitigate intestinal inflammation and carcinogenesis, as well as modulate intestinal microbial composition. To further translate findings from preclinical models, we hypothesized that mango polyphenols possess anti-inflammatory and microbiome-modulatory activities and may improve symptoms of IBD, reduce biomarkers for inflammation and modulate the intestinal microbiome when administered as an adjuvant treatment in combination with conventional medications in patients with mild to moderate IBD. In this study, ten participants received a daily dose of 200-400 g of mango pulp for 8 weeks (NCT02227602). Mango intake significantly improved the primary outcome Simple Clinical Colitis Activity Index (SCCAI) score and decreased the plasma levels of pro-inflammatory cytokines including interleukin-8 (IL-8), growth-regulated oncogene (GRO) and granulocyte macrophage colony-stimulating factor (GM-CSF) by 16.2% (P = .0475), 25.0% (P = .0375) and 28.6% (P = .0485), all factors related to neutrophil-induced inflammation, respectively. Mango intake beneficially altered fecal microbial composition by significantly increasing the abundance of Lactobacillus spp., Lactobacillus plantarum, Lactobacillus reuteri and Lactobacillus lactis, which was accompanied by increased fecal butyric acid production. Therefore, enriching diet with mango fruits or potentially other gallotannin-rich foods seems to be a promising adjuvant therapy combined with conventional medications in the management of IBD via reducing biomarkers of inflammation and modulating the intestinal microbiota.
炎症性肠病（IBD）以慢性肠道炎症和肠道微生物失调为特征，是结直肠癌发展的主要危险因素。先前，芒果（Mangifera indica L.）中的膳食多酚，如缩合单宁和没食子酸，已被证明可减轻肠道炎症和致癌作用，并调节肠道微生物组成。为了进一步将临床前模型的研究结果转化，我们假设芒果多酚具有抗炎和微生物组调节作用，当作为辅助治疗与常规药物联合用于轻中度 IBD 患者时，可能改善 IBD 症状，降低炎症生物标志物，并调节肠道微生物组。在这项研究中，十名参与者接受了 8 周的每天 200-400 克芒果果肉剂量（NCT02227602）。芒果摄入量显著改善了主要结局简单临床结肠炎活动指数（SCCAI）评分，并降低了促炎细胞因子的血浆水平，包括白细胞介素-8（IL-8）、生长调节癌基因（GRO）和粒细胞巨噬细胞集落刺激因子（GM-CSF），分别为 16.2%（P =.0475）、25.0%（P =.0375）和 28.6%（P =.0485），所有这些因素都与中性粒细胞诱导的炎症有关。芒果摄入量通过显著增加乳杆菌属、植物乳杆菌、罗伊氏乳杆菌和乳酸乳杆菌的丰度，有益地改变了粪便微生物组成，同时粪便丁酸产量增加。因此，通过减少炎症生物标志物和调节肠道微生物群，用芒果果实或潜在的其他富含缩合单宁的食物丰富饮食似乎是一种有前途的辅助治疗方法，可与常规药物联合用于 IBD 的治疗。
